Assenagon Asset Management S.A. Protagonist Therapeutics, Inc Transaction History
Assenagon Asset Management S.A.
- $60.5 Billion
- Q2 2025
A detailed history of Assenagon Asset Management S.A. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 91,875 shares of PTGX stock, worth $4.58 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
91,875
Previous 44,872
104.75%
Holding current value
$4.58 Million
Previous $2.17 Million
133.96%
% of portfolio
0.01%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
302Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$305 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$287 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$285 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$213 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$150 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.45B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...